

# Venceslau Pinto Hespanhol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/754582/publications.pdf>

Version: 2024-02-01

43  
papers

2,995  
citations

471509

17  
h-index

302126

39  
g-index

47  
all docs

47  
docs citations

47  
times ranked

4141  
citing authors

#	ARTICLE	IF	CITATIONS
1	COPD: How can evidence from randomised controlled trials apply to patients treated in everyday clinical practice?. Pulmonology, 2022, 28, 431-439.	2.1	6
2	Towards Machine Learning-Aided Lung Cancer Clinical Routines: Approaches and Open Challenges. Journal of Personalized Medicine, 2022, 12, 480.	2.5	19
3	Multiple instance learning for lung pathophysiological findings detection using CT scans. Medical and Biological Engineering and Computing, 2022, 60, 1569-1584.	2.8	4
4	The VacinÃ³metro® initiative: an eleven-year monitorization of influenza vaccination coverage rates among risk groups in Portugal. Pulmonology, 2022, 28, 427-430.	2.1	2
5	<i>EGFR</i> Assessment in Lung Cancer CT Images: Analysis of Local and Holistic Regions of Interest Using Deep Unsupervised Transfer Learning. IEEE Access, 2021, 9, 58667-58676.	4.2	24
6	Machine Learning and Feature Selection Methods for EGFR Mutation Status Prediction in Lung Cancer. Applied Sciences (Switzerland), 2021, 11, 3273.	2.5	21
7	Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer. Cancers, 2021, 13, 2707.	3.7	8
8	Sharing Biomedical Data: Strengthening AI Development in Healthcare. Healthcare (Switzerland), 2021, 9, 827.	2.0	8
9	Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper. Drug Safety, 2021, 44, 825-834.	3.2	5
10	Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic. Cells, 2021, 10, 1912.	4.1	13
11	Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images. Journal of Clinical Medicine, 2021, 10, 118.	2.4	14
12	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. Cancer Cell International, 2021, 21, 675.	4.1	9
13	Pneumonia mortality, comorbidities matter?. Pulmonology, 2020, 26, 123-129.	2.1	61
14	Is an Early Diagnosis of COPD Clinically Useful?. Archivos De Bronconeumologia, 2020, 56, 409-410.	0.8	4
15	Is an Early Diagnosis of COPD Clinically Useful?. Archivos De Bronconeumologia, 2020, 56, 409-410.	0.8	2
16	Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS. Scientific Reports, 2020, 10, 3625.	3.3	41
17	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation. Cancers, 2019, 11, 1229.	3.7	23
18	Quo Vadisâ€¦ Pneumonia. Pulmonology, 2019, 25, 65.	2.1	0

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor DNA: A Step into the Future of Cancer Management. <i>Acta Cytologica</i> , 2019, 63, 456-465.	1.3	13
20	Chronic Bacterial Infection Prevalence, Risk Factors, and Characteristics: A Bronchiectasis Population-Based Prospective Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 315.	2.4	3
21	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	13.7	2,347
22	Discordance between old and new criteria for stratifying patients with COPD. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190183.	0.7	0
23	Lung cancer: a brief review of epidemiology and screening. <i>Future Oncology</i> , 2018, 14, 567-575.	2.4	24
24	Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. <i>Archivos De Bronconeumologia</i> , 2018, 54, 10-17.	0.8	0
25	Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. <i>Archivos De Bronconeumologia</i> , 2018, 54, 10-17.	0.8	17
26	COPD: understanding patients&rsquo; adherence to inhaled medications. <i>International Journal of COPD</i> , 2018, Volume 13, 2767-2773.	2.3	40
27	¿Es Ã³til el concepto de control de la EPOC?: evaluaciÃ³n del Ã©xito terapÃ©utico a partir de la valoraciÃ³n del estado de salud en relaciÃ³n con la EPOC. <i>Archivos De Bronconeumologia</i> , 2017, 53, 530-531.	0.8	5
28	The Role of Angiogenesis in Non-small Cell Lung Cancer Tumor Behavior. , 2017, , 217-239.		0
29	Cancro do pulmÃ£o no norte de Portugal: um estudo de base hospitalar. <i>Revista Portuguesa De Pneumologia</i> , 2013, 19, 245-251.	0.7	11
30	Neoplastic severe central airways obstruction, interventional bronchoscopy: A decision-making analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 926-932.	0.8	22
31	Role of Genetic Polymorphisms in the Angiogenesis Pathway and Non-small-Cell Lung Cancer Tumor Behavior: Implications in Risk Assessment and Clinical Outcome. , 2013, , 381-403.		3
32	The Impact of Polymorphic Variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the Risk and Prognosis of Portuguese Patients with Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e72373.	2.5	26
33	Loci identified through genome-wide association studies and lung cancer risk: is there anything more?. <i>Sao Paulo Medical Journal</i> , 2013, 131, 135-136.	0.9	5
34	Pulmonary Rehabilitation in Patients With Bronchiectasis. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2012, 32, 278-283.	2.1	35
35	Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2012, 7, 118-131.	1.6	29
36	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. <i>Tumor Biology</i> , 2012, 33, 2061-2068.	1.8	30

#	ARTICLE	IF	CITATIONS
37	Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study. <i>Tumor Biology</i> , 2012, 33, 1341-1348.	1.8	17
38	Sialylation regulates galectin-3/ligand interplay during mammary tumour progression - a case of targeted uncloaking. <i>International Journal of Developmental Biology</i> , 2011, 55, 823-834.	0.6	24
39	Henoch-Schonlein purpura: a clinical case with dramatic presentation. <i>BMJ Case Reports</i> , 2010, 2010, bcr1220092555-bcr1220092555.	0.5	0
40	Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis. <i>Glycobiology</i> , 2010, 20, 1341-1352.	2.5	30
41	MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features. <i>Veterinary Journal</i> , 2009, 182, 491-493.	1.7	17
42	Endobronchial Amyloidosis. <i>Journal of Bronchology</i> , 2008, 15, 95-99.	0.2	4
43	Rigid Bronchoscopy. <i>Journal of Bronchology</i> , 2003, 10, 177-182.	0.2	19